Vertex Names Jonathan Poole Finance Chief as Crinetics Buy Closes
Vertex Pharmaceuticals Inc VX1
News
Vertex Shares Rise as Rival Sionna's Cystic-Fibrosis Trial Fails to Meet Endpoint
Vertex Pharmaceuticals Bumps Up Fiscal Year Outlook on Growth of Cystic Fibrosis Drugs
Vertex Pharmaceuticals Currently Down Seven Consecutive Days, on Pace for Longest Losing Streak Since August 2021 — Data Talk
Cantor Sees 'Clear Strategic Rationale' Behind Vertex's Buy of Crinetics — Market Talk
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
Vertex Pharmaceuticals Gets FDA OK for Sickle Cell Disease Treatment in Young Children
Vertex Pharmaceuticals Says New Pain Management Drug Is Under Review at Health Canada
Vertex Pharmaceuticals Ends Study of Cystic Fibrosis Drug Over Tolerability Issues
Vertex Pharmaceuticals Posts Higher 1Q Profit
Vertex Pharmaceuticals Up Over 9%, on Pace for Largest Percent Increase Since December 2023 — Data Talk
Vertex Pharmaceuticals Up Over 6%, On Track for Highest Close Since May 2025 — Data Talk
Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand
Vertex Pharmaceuticals Up Over 5%, on Pace for Largest Percent Increase Since November 2024 — Data Talk
Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs
Vertex Pharma to Submit Kidney-Disease Drug Application to FDA by Year-End
Vertex Pharmaceuticals On Track for Largest Percent Increase Since January — Data Talk
FDA Grants Vertex Kidney Disease Drug Breakthrough Therapy Designation
United States